future of glp 1 drugs Are GLP-1 weight-loss quietly reshaping how people eat? Could reduced appetite and smaller portion sizes change the food innovation? And what does this shift mean for the growing role The GLP-1 revolution: What UAB

In 2021, Wegovy ( semaglutide) became the other GLP-1 approved for weight loss, although its lower-dose sibling Ozempic was approved for diabetes in 2017

At the same time, Akt phosphorylates and inactivates forkhead box O (FoxO), thereby inhibit the responsible for proteolysis ubiquitin ligases: muscle-specific RING finger-1 (MuRF-1) and muscle atrophy F-box protein (atrogin-1), (for review see [27,28,29])

Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February

PMCID: PMC5621476

doi:10.1093/advances/nmy057 de Ligny W, Smits RM, Mackenzie-Proctor R, et al